DNA Repair Pathway Found to Be Cancer Weakness | Scripps Research

The relentless activity within our cells—growth, division, and repair—comes at a cost: constant damage to DNA. While healthy cells possess robust mechanisms to mend these breaks, cancer cells sometimes exploit a less precise, emergency repair pathway to survive. New research from Scripps Research sheds light on how this backup system is activated and, crucially, how its dependence could be turned into a therapeutic vulnerability. Understanding this process offers a potential new avenue for targeting cancers that rely on this flawed repair strategy.

R-Loops and Genome Instability: A Dangerous Combination

At the heart of this discovery lies the role of RNA-DNA tangles, known as R-loops. These structures form when newly created RNA doesn’t fully separate from the DNA template it was copied from, leaving a single strand of DNA exposed. While R-loops have normal cellular functions, their accumulation can lead to genome instability – a hallmark of cancer. “R-loops are important for many different cell functions, but they must be tightly controlled,” explains Xiaohua Wu, a professor at Scripps Research and senior author of the study published in Cell Reports. “If they aren’t properly regulated, they can accumulate to harmful levels and cause genome instability.”

The SETX Gene: A Link Between Neurological Disorders and Cancer

The research focuses on a protein called senataxin (SETX), a helicase responsible for untangling these genetic knots. Mutations in the SETX gene are known to cause rare neurological conditions like ataxia and a form of amyotrophic lateral sclerosis (ALS). Intriguingly, these same mutations also appear in some uterine, skin, and breast cancers. This raised a critical question: how do cancer cells cope with the buildup of R-loops when SETX is defective or missing? The answer, it turns out, involves a risky fallback repair mechanism.

Break-Induced Replication: An Emergency Repair Pathway

When cells lacking functional SETX experience double-strand breaks – where both strands of the DNA helix are severed – they activate a repair process called break-induced replication (BIR). BIR isn’t the cell’s preferred method for fixing DNA. Normally, cells use highly accurate systems to repair these breaks. BIR is a last resort, copying large stretches of DNA to reconnect broken pieces. While it can save the cell from immediate disaster, it’s prone to errors. As Wu puts it, “It’s like an emergency repair team that works intensively but makes more mistakes.”

The Scripps Research team discovered that in SETX-deficient cells, R-loops accumulate directly at the sites of DNA breaks. This accumulation disrupts the normal repair signals, causing the cell to excessively trim the broken DNA ends, exposing long stretches of single-stranded DNA. This exposed DNA then attracts the machinery needed for BIR, including a helicase called PIF1, effectively triggering the emergency repair process. The study details this intricate interplay between R-loop accumulation, DNA damage, and the activation of BIR.

Synthetic Lethality: Exploiting a Cancer Cell’s Weakness

While BIR allows SETX-deficient cells to survive, it also creates a vulnerability. These cells become dependent on BIR to repair DNA damage. Blocking this repair pathway leads to the accumulation of irreparable breaks and cell death. This concept, known as synthetic lethality, is already leveraged in cancer treatments – targeting a weakness present in cancer cells but absent in healthy cells. The researchers identified three BIR-related proteins – PIF1, RAD52, and XPF – that are particularly crucial for the survival of SETX-deficient cells. “What’s important is that these aren’t essential in normal cells, which means we could selectively kill SETX-deficient tumors,” Wu explains.

Beyond SETX: The Broader Implications for Cancer Therapy

Although SETX deficiency is relatively rare, the underlying principle of R-loop accumulation and BIR activation may be relevant to a wider range of cancers. Many tumors develop R-loops through other mechanisms, such as oncogene activation or hormone signaling, like estrogen in certain breast cancers. This suggests that targeting BIR could be a viable strategy for treating a more substantial number of patients. Research into nuclear and genome dynamics further supports the idea that manipulating DNA repair pathways can offer new therapeutic avenues.

The Future of BIR-Targeted Therapies

Wu’s team is now focused on developing inhibitors that can block the activity of BIR-related proteins. The challenge lies in finding compounds that are both effective and have minimal toxicity to healthy cells. They are also working to identify which cancers exhibit the highest levels of R-loops and are most likely to respond to BIR-targeted therapies. This involves investigating the specific conditions that lead to R-loop accumulation in different tumor types.

While clinical applications are still some time away, the findings represent a significant step forward in understanding how cancer cells exploit DNA repair mechanisms to survive. The research highlights the potential of synthetic lethality as a powerful approach to developing more targeted and effective cancer treatments. Further investigation into the interplay between R-loops, DNA damage repair, and genome stability promises to unlock new strategies for combating this complex disease.